Abstract
From November 1981 to February 1983, 64 patients with advanced head and neck squamous carcinoma were randomly treated with either high-dise (120 mg/m2) or low-dose (60 mg/m2) cisplatin. Of the 62 eligible patients, 59 were evaluable: the response rate observed in patients receiving high-dose and low-dose cisplatin was 16.1% and 17.8%, respectively. Survival was superimposable in the two treatment arms. No evidence of dose dependency of cisplatin activity in advanced head and neck squamous carcinoma was noted in this randomized trial.
| Original language | English |
|---|---|
| Pages (from-to) | 1105-1108 |
| Number of pages | 4 |
| Journal | Journal of Clinical Oncology |
| Volume | 3 |
| Issue number | 8 |
| Publication status | Published - 1985 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma : A randomized study. / Veronesi, A.; Zagonel, V.; Tirelli, U.; Galligioni, E.; Tumolo, S.; Barzan, L.; Lorenzini, M.; Comoretto, R.; Grigoletto, E.
In: Journal of Clinical Oncology, Vol. 3, No. 8, 1985, p. 1105-1108.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma
T2 - A randomized study
AU - Veronesi, A.
AU - Zagonel, V.
AU - Tirelli, U.
AU - Galligioni, E.
AU - Tumolo, S.
AU - Barzan, L.
AU - Lorenzini, M.
AU - Comoretto, R.
AU - Grigoletto, E.
PY - 1985
Y1 - 1985
N2 - From November 1981 to February 1983, 64 patients with advanced head and neck squamous carcinoma were randomly treated with either high-dise (120 mg/m2) or low-dose (60 mg/m2) cisplatin. Of the 62 eligible patients, 59 were evaluable: the response rate observed in patients receiving high-dose and low-dose cisplatin was 16.1% and 17.8%, respectively. Survival was superimposable in the two treatment arms. No evidence of dose dependency of cisplatin activity in advanced head and neck squamous carcinoma was noted in this randomized trial.
AB - From November 1981 to February 1983, 64 patients with advanced head and neck squamous carcinoma were randomly treated with either high-dise (120 mg/m2) or low-dose (60 mg/m2) cisplatin. Of the 62 eligible patients, 59 were evaluable: the response rate observed in patients receiving high-dose and low-dose cisplatin was 16.1% and 17.8%, respectively. Survival was superimposable in the two treatment arms. No evidence of dose dependency of cisplatin activity in advanced head and neck squamous carcinoma was noted in this randomized trial.
UR - http://www.scopus.com/inward/record.url?scp=0021843171&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021843171&partnerID=8YFLogxK
M3 - Article
VL - 3
SP - 1105
EP - 1108
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 8
ER -